Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- LEO PharmaLEO Pharma Further Strengthens Late-Stage Pipeline With the Acquisition of DersimelagonBALLERUP, Denmark, August 18, 2026--LEO Pharma, a global leader in medical dermatology delivering innovative solutions for skin disease, today announces that it has entered into an agreement to acquire worldwide rights to dersimelagon from Tanabe Pharma. Dersimelagon is an oral, once-daily small MC1R agonist being developed for EPP and XLP.
- Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in AustraliaHansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication...
- Ingenia Therapeutics Goes Public on KOSDAQ to Accelerate Pipeline of Next-Generation Vascular Antibody TherapeuticsWATERTOWN, Mass., August 18, 2026--Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced today that its shares have begun trading on the KOSDAQ market. The IPO marks a significant milestone as the company accelerates the development and global commercialization of its proprietary vascular stabilization pipeline.
- Tokyo Lifestyle Receives Independent Research Coverage from Broad Investment Securities; Note Highlights Asset-Light Shift and Global ExpansionNEW YORK, Aug 18, 2026 - Broad Investment Securities LLC, a U.S. SEC-registered investment adviser, has issued an independent fundamental research report on Tokyo Lifestyle Co., Ltd. (Nasdaq: TKLF), examining the Japanese consumer-products distributor’s business model, financial trajectory, channel mix and international expansion. Tokyo Lifestyle, formerly Yoshitsu Co., Ltd., operates as a retailer and wholesaler of Japanese beauty and health products, general merchandise, luxury goods, electronics and collectible cards. The company reaches end markets through four channels—company-operated stores, franchise outlets, wholesale distribution and cross-border e-commerce—across Japan, Hong Kong, Southeast Asia, North America, the UK and Australia. Its assortment spans roughly 69,800 SKUs. Supplier relationships include major Japanese brands such as Shiseido, Kao and Kose. The company also manages proprietary and licensed brands including Tokyo Lifestyle, Hare no Ryohin and REIWATAKIYA. In 2025 it began private-label product development and entered a strategic collaboration with an affiliate of Tasly Group aimed at joint research, development and global distribution of health products. As of the fiscal year ended March 31, 2026, Tokyo Lifestyle reported nine franchise partners operating 11 stores in the United States, the UK, Hong Kong, Thailand, Vietnam and Japan. Hong Kong continues to serve as the primary logistics and distribution hub linking Japanese supply chains to overseas markets. Net revenue for FY2026 rose 77.6% year-on-year to $373.2 million, the highest level since the company’s January 2022 Nasdaq listing. Revenue expanded from approximately $195.7 million in FY2024 to $210.1 million in FY2025 before accelerating to $373.2 million. The increase was driven principally by faster growth in the franchise and wholesale channels and by an expanded contribution from luxury goods, consistent with management’s stated transition from an asset-heavy company-operated model toward a lighter franchise-and-wholesale structure. Gross margin contracted from 11.4% in FY2025 to 7.5% in FY2026. Net income attributable to the company was about $0.72 million, or basic earnings per share of $0.02. The margin compression reflects the rising weighting of franchise and wholesale sales, which typically generate lower unit margins in exchange for greater scale and reduced capital intensity. The company remains in the investment phase of this strategic shift; the path to sustained profitability is still evolving. Geographic mix continued to internationalize. Japan accounted for 52.9% of FY2026 revenue, down from 70.5% a year earlier, while Hong Kong and other overseas markets rose to 47.1% from 29.5%. Total assets increased to $233.6 million from $157.8 million, of which accounts receivable stood at $186.8 million. Operating cash flow was negative during the period, primarily reflecting the working-capital build associated with expansion. At the July 29, 2026 close, the shares traded at $2.025 per ADS, implying a market capitalization of approximately $8.57 million, a trailing price-to-earnings ratio of about 11.96 and a price-to-book ratio of roughly 0.21. As a micro-cap issuer, Tokyo Lifestyle remains subject to Nasdaq continued-listing requirements as well as balance-sheet and cash-flow considerations, points the research note addresses directly. Overall, the report positions Tokyo Lifestyle as a relatively scarce Nasdaq-listed Japanese cross-border consumer-products platform with above-average top-line growth and a distinctly international revenue profile, while underscoring the operational and financial characteristics typical of a micro-cap company still executing a structural transition. For more information, please contact: Golden Fleece Cross-border Consulting Co., Limited Email: [email protected]
- Enginprime Medical Inc; Voyagers CapitalEnginprime Medical Closes $12M Series A FinancingRound exclusively led by Qiming Venture Partners; proceeds to fund China registration trial and overseas early-stage clinical development — Enginprime Medical ("Enginprime" or the "Company"), a developer of percutaneous ventricular...
- TekniPlex Healthcare Showcases Locally Manufactured Extrusion Solutions for China’s Medical Device Market at Medtec China 2026Company will highlight medical silicone pump tubing, Para-tubing solutions for ophthalmic applications, and PTA/PTCA precision interventional tubing technologies to support medical device innovation
- Affordable Spine Surgery in India: Exceptional Care for Global PatientsAccess cost-effective spine surgery with advanced medical expertise, modern facilities, and compassionate care for international patients.
- Speakeasy DispensarySpeakeasy Dispensary Opens New Ward Location, Expanding Patient Access in Central ArkansasFormer Pine Bluff dispensary relocates to Ward, bringing medical cannabis access closer to patients in an underserved area of the state. — Speakeasy Dispensary will officially open the doors to its new Ward location on Thursday, August 20 at 9 am....
- Robbins LLPDid You Lose Money Investing in Replimune Group, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About their Rights Against REPLShareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Replimune Group, Inc. (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026 ("Class Period"). Replimune purports to be a clinical-stage biotechnology company focused on novel oncolytic immunotherapies. According to the complaint, the Company's lead product...
- BD (Becton, Dickinson and Company)BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to RetireCompanies: Becton DickinsonBD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8. Sorsher brings more...
- Sagimet Biosciences Inc.Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in connection with the hiring of 3 employees, the Compensation Committee of Sagimet’s Board of Directors approved that an inducement grant of 260,700 stock options in aggregate to purchase shares of the Company’s Series A common stock be granted on August 17, 2026 to the newly hired employees.
- DocGo Inc.DocGo Announces Second Quarter 2026 ResultsNEW YORK, August 17, 2026--DocGo Inc. (Nasdaq: DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health and medical transportation services, today announced financial and operating results for the second quarter ended June 30, 2026.